Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)

被引:60
|
作者
Ugwu, F
Van Hoef, B
Bini, A
Collen, D
Lijnen, HR
机构
[1] Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium
[2] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Blood Coagulat Biochem, New York, NY 10021 USA
关键词
D O I
10.1021/bi9728708
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinase-3 (MMP-3, or stromelysin-1) specifically hydrolyzes the Glu(143)-Leu(144) peptide bond in 45-kDa single-chain urokinase-type plasminogen activator (scu-PA) and in its two-chain (tcu-PA) derivative, yielding a 17-kDa NH2-terminal domain comprising the u-PA receptor (u-PAR) binding site and a 32-kDa COOH-terminal moiety containing the serine proteinase domain of u-PA. The conversion is completely abolished in the presence of the MMP inhibitors EDTA or 1,10-phenanthroline. Biospecific interaction analysis indicates that binding of MMP-3 occurs through the 32-kDa fragment. The 32-kDa fragment derived from scu-PA (scu-PA-32k) has a specific activity of less than or equal to 500 IU/mg, but it can be activated with plasmin to a two-chain derivative (tcu-PA-32k) with a specific activity of 79 000 IU/mg, tcu-PA and tcu-PA-32k moieties derived from scu-PA-32k by plasmin or from tcu-PA by MMP-3 have comparable amidolytic activities toward the chromogenic substrate S-2444 (k(cat)/K-m of 110 and 160 mM(-1) s(-1), respectively) and similar plasminogen activating activities in a coupled chromogenic substrate assay. Specific binding of the 17-kDa NH2-terminal domain to THP-1 monocytoid cells is completely abolished by competition with scu-PA but is not affected by scu-PA-32k (residual binding of 88 +/- 9% (mean +/- SEM; n = 3) with 25-fold molar excess). Thus, MMP-3 removes a functional NH2-terminal u-PAR-binding domain from u-PA without affecting its enzymatic properties.
引用
收藏
页码:7231 / 7236
页数:6
相关论文
共 50 条
  • [21] Urokinase-type plasminogen activator, an endogenous antibiotic
    Jin, T
    Bokarewa, M
    Tarkowski, A
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03): : 429 - 437
  • [22] Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator Receptor
    Reichel, Christoph A.
    Uhl, Bernd
    Lerchenberger, Max
    Puhr-Westerheide, Daniel
    Rehberg, Markus
    Liebl, Johanna
    Khandoga, Andrej
    Schmalix, Wolfgang
    Zahler, Stefan
    Deindl, Elisabeth
    Lorenzl, Stefan
    Declerck, Paul J.
    Kanse, Sandip
    Krombach, Fritz
    CIRCULATION, 2011, 124 (17) : 1849 - U193
  • [23] Macromolecular inhibition of urokinase-type plasminogen activator
    Laboissière, MCA
    Yang, Q
    Craik, CS
    FASEB JOURNAL, 1997, 11 (09): : A1397 - A1397
  • [24] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [25] Nuclear translocation of urokinase-type plasminogen activator
    Stepanova, Victoria
    Lebedeva, Tatiana
    Kuo, Alice
    Yarovoi, Serge
    Tkachuk, Sergei
    Zaitsev, Sergei
    Bdeir, Khalil
    Durnler, Inna
    Marks, Michael S.
    Parfyonova, Yelena
    Tkachuk, Vsevolod A.
    Higazi, Abd Al-Roof
    Cines, Douglas B.
    BLOOD, 2008, 112 (01) : 100 - 110
  • [26] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND MALIGNANCY
    DUFFY, MJ
    FIBRINOLYSIS, 1993, 7 (05) : 295 - 302
  • [27] Ras regulation of urokinase-type plasminogen activator
    Lengyel, E
    Ried, S
    Heiss, MM
    Jäger, C
    Schmitt, M
    Allgayer, H
    REGULATORS AND EFFECTORS OF SMALL GTPASES, PT G, 2001, 333 : 105 - 116
  • [28] Inhibition of stromelysin-1 (MMP-3) by P-1'-biphenylylethyl carboxyalkyl dipeptides
    Esser, CK
    Bugianesi, RL
    Caldwell, CG
    Chapman, KT
    Durette, PL
    Girotra, NN
    Kopka, IE
    Lanza, TJ
    Levorse, DA
    MacCoss, M
    Owens, KA
    Ponpipom, MM
    Simeone, JP
    Harrison, RK
    Niedzwiecki, L
    Becker, JW
    Marcy, AI
    Axel, MG
    Christen, AJ
    McDonnell, J
    Moore, VL
    Olszewski, JM
    Saphos, C
    Visco, DM
    Shen, F
    Colletti, A
    Krieter, PA
    Hagmann, WK
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) : 1026 - 1040
  • [29] Urokinase-type plasminogen activator inhibitors.
    Squires, N
    McGee, D
    Allen, D
    Hruzewicz, W
    Spencer, J
    Sprengeler, P
    Katz, B
    Luong, C
    Mackman, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U51 - U51
  • [30] Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator
    Jo, MJ
    Thomas, KS
    Marozkina, N
    Amin, TJ
    Silva, CM
    Parsons, SJ
    Gonias, SL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 17449 - 17457